<DOC>
	<DOCNO>NCT02579226</DOCNO>
	<brief_summary>This Phase I study primarily design evaluate safety tolerability AZD2811 increase dos patient advance solid tumour standard care exist . The study conduct two part , dose-escalation phase ( Part A ) dose expansion phase ( Part B ) . During Part A , dose-escalation phase , patient enrolment proceed accord 3+3 design maximum tolerate dose ( MTD ) recommend Phase II dose ( RP2D ) identify . The study also characterize pharmacokinetic ( PK ) profile AZD2811 explore potential biological activity assess anti-tumour activity patient . Once MTD establish , Part B ( dose expansion phase ) commence enroll patient 3 group . Part B explore PK parameter , safety , tolerability , preliminary anti-tumour activity AZD2811 RP2D monotherapy ( Group 1 ) patient relapsed/refractory SCLC , combine irinotecan ( Group 2 Group 3 ) . In Part B-Group 2 , PK , safety tolerability AZD2811 assess lead-in cohort give combination irinotecan . When safe tolerate dose AZD2811 irinotecan combination define , additional 30 patient enrol assess efficacy ( Part B-Group 3 ) .</brief_summary>
	<brief_title>A Phase I Study Safety , Tolerability , PK AZD2811 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This FTIP study primarily design evaluate safety tolerability AZD2811 increase dos patient advance solid tumour standard care exist . The study conduct two part , dose-escalation phase ( Part A ) patient advance metastatic solid tumour , dose-expansion phase ( Part B ) patient relapsed/refractory SCLC . During Part A , dose-escalation phase , patient enrolment proceed accord 3+3 design maximum-tolerated dose ( MTD ) recommend Phase 2 dose ( RP2D ) identify . The study also characterize PK profile AZD2811 explore potential biological activity assess anti-tumour activity patient . Once MTD establish , Part B , dose-expansion phase , enroll patient 3 group . Part B explore PK parameter , safety , tolerability , preliminary anti-tumour activity AZD2811 RP2D monotherapy ( Group 1 ) patient relapsed/refractory SCLC , combine irinotecan ( Group 2 Group 3 ) . In Group 2 , PK , safety tolerability AZD2811 irinotecan combination brief lead-in cohort assess . Once safe tolerate dose AZD2811 irinotecan combination define , additional 30 patient enrol assess efficacy ( Group 3 ) .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Part A dose escalation 1 . Histological cytological confirmation solid tumour disease progression despite standard therapy ( y ) , must intolerant standard therapy ( y ) , standard therapy exists . 2 . Patients must receive ≤3 prior chemotherapy regimen metastatic setting may include irinotecan . Part B dose expansion 1 . Patients must receive least 1 prior therapy 2 prior regimen relapse and/or refractory SCLC . No previous treatment irinotecan enter Part B , Group 2 3 . 2 . Measurable evaluable disease accord RECIST v1.1 . 3 . Aged least 18 year . 4 . Adequate organ system function , outline : Absolute neutrophil count ( ANC ) ≥1.5 X 109/L Platelets ≥100 X 109/L Hemoglobin ≥9g/dL PT/PTT/INR ≤1.5 x upper limit normal ( ULN ) Total bilirubin ≤1.5 mg/dL ALT AST ≤3.0 time ULN liver involvement ≤5 time ULN liver involvement . Creatinine ≤1.5 x ULN , OR calculate measure creatinine clearance ≥50 mL/min , OR 24hour measure urine creatinine clearance ≥50 mL/min . 5 . ECOG performance status 01 . 6 . Predicted life expectancy ≥12 week . 7 . Females use adequate contraceptive measure time screen 6 month study discontinuation , breast feeding must negative pregnancy test prior start dose . 1 . Patients treat recent radiotherapy , hormonal therapy , immunotherapy , chemotherapy investigational drug within ≤21 day 5 halflives ( whichever short ) enrolment ( screen ) , and/or unresolved NCI Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 &gt; Grade 1 treatmentrelated side effect , exception alopecia , enrol . 2 . Major surgery ( exclude placement vascular access ) ≤21 day begin study drug minor surgical procedure ≤7 day . No wait require follow implantable port catheter placement . 3 . Previous treatment alisertib . 4 . Any following cardiac criterion : Congestive heart failure ( CHF ) per New York Heart Association ( NYHA ) classification &gt; Class II Cardiac ventricular arrhythmia require antiarrhythmic therapy Unstable angina newonset angina QTcF interval &gt; 470 m screen ECG . 5 . Active noninfectious skin disease ( include grade rash , urticarial , dermatitis , ulceration , psoriasis ) . 6 . Patients diarrhea NCI CTCAE v4.03 Grade ≥2 . 7 . Patient prescription nonprescription drug product know strong inhibitors/inducers CYP3A4 discontinue prior Day 1 dose withheld throughout study 2 week last dose study drug . 8 . Any evidence active infection , severe uncontrolled systemic disease include uncontrolled hypertension , active bleeding diatheses , hepatitis B , hepatitis C human immunodeficiency virus . 9 . Previously untreated brain metastasis . Patients receive radiation surgery brain metastasis eligible therapy complete least 3 week previously evidence central nervous system disease progression , mild neurologic symptom , requirement chronic corticosteroid therapy . 10 . Treatment haematopoietic colonystimulating factor ( e.g. , GCSF ) ≤2 week prior screen visit . 11 . Lactating , breastfeeding , positive pregnancy test female patient childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AZD2811</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Advanced solid tumour</keyword>
</DOC>